Tuesday, July 5, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Identification of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding

by Medical Finance
in Coronavirus
Study: Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening. Image Credit: Zerbor/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to the bioRxiv* preprint server, researchers discovered compounds able to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) macrodomain 1 (Mac1) and adenosine diphosphate (ADP)-ribose binding via high throughput screening. 

Study: Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening. Image Credit: Zerbor/Shutterstock
Study: Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening. Image Credit: Zerbor/Shutterstock

Background

In the last two decades, the emergence of various zoonotic viruses, especially the SARS-CoV-2 outbreak, has revealed the scarcity of antiviral medication therapy for viruses with pandemic potential. To date, coronavirus disease 2019 (COVID-19) has claimed 6 million lives and caused 446 million cases worldwide.

Our capacity to respond quickly to new CoVs and various other viruses with pandemic potential will be dependent on developing a broader antiviral drug portfolio. Hence there is an urgent need for devising broad-spectrum antiviral therapies directed towards a wide span of CoVs to combat severe illness during the ongoing SARS-CoV-2 pandemic and future zoonotic outbreaks.

About the study

In the present study, the researchers analyzed some molecules that could inhibit binding between SARS-CoV-2’s conserved Mac1 and ADP-ribose. For this, the team optimized a luminescent-based high throughput assay named AlphaScreenTM (AS) and a novel fluorescence polarization (FP) assay.

Further, they used AS assay to screen approximately 38,000 small molecules to detect their ability to hinder SARS-CoV-2 Mac1-ADP-ribose binding. The researchers also determined the direct binding of these compounds to the Mac1. The ability of the compounds to restrain Mac1-ADP-ribose binding was compared between Mac1s of SARS-CoV-2, Middle East respiratory syndrome CoV (MERS-CoV), SARS-CoV, and human macrodomain MDO2.

Findings

The results show that the Mac1 from SARS-CoV-2, MERS-CoV, and SARS-CoV, and the human macrodomain MDO2 bound to ADP-ribosylated control peptides better than non-ADP-ribosylated peptides in the AS and FP assays. The human MDO2 had a heightened affinity to peptides in dose-dependent AS and FP experiments relative to SARS-CoV-2, MERS-CoV, and SARS-CoV Mac1s. The supplementation of free ADP-ribose, but not adenosine triphosphate (ATP), decreased CoV Mac1 and human macrodomain binding to ADP-ribosylated peptides in the AS and FP assays. 

The half-maximal inhibitory concentration (IC50) values for free ADP-ribose varied between 0.24 µM to 1.5 µM with SARS-CoV-1 and SARS-CoV-2, respectively, in the AS assay. In addition, the IC50 values ranged from 2.3 µM to 9.74 µM for SARS-CoV-1 and COV-2, respectively, in the FP assay. This observation proves that these assays could be utilized to find macrodomain binding inhibitors.

Of the 406 original hits from the Peptidomimetics, three-dimensional (3D) BioDiversity, and Analyticon libraries, 26 compounds hindered the ADP-ribose-SARS-CoV-2 Mac1 binding in an exposure-response manner in the AS assay, and six compounds inhibited Mac1 binding in FP and AS assays. Compounds 1, 2, 6, 7, 10, and 11. Compounds 11, 10, and 1 also displayed inhibitory potential towards Mac1 of MERS-CoV, although lower than that towards SARS-CoV-2’s Mac1. Further, only compound 2 hindered MDO2, suggesting that the other compounds were selective towards viral macrodomains.

The supplementation of free ADP-ribose demonstrated a dose-dependent elevation of about 4℃ in the melting temperature of SARS-CoV-2 Mac1, whereas ATP had no impact in the differential scanning fluorimetry (DSF) assay. The hike in melting temperature of Mac1 was linked to the binding of the compound to Mac1. The melting temperature of Mac1 changed in a dose-dependent manner in compounds 11, 10, 7, 6, and 1.

Compounds 7, 6, and 1 demonstrated a dose-dependent hindrance of Mac1 ADP-ribosylhydrolase activity in a gel-based Mac1 ADP-ribosylhydrolase experiment. In contrast, all six compounds showed dose-dependent inhibition of ADP-ribosylhydrolase activity in the recently published high-throughput luminescence-based ADP-ribosylhydrolase test. However, compound 6 was the most efficient inhibitor of ADP-ribosylhydrolase activity versus others.

Out of 16 distinct viral and human macrodomains in the recently established fluorescence resonance energy transfer (FRET)-based assay, compound 6 substantially inhibited the SARS-CoV-2 Mac1. This inference implies the selectivity of compound 6 towards the Mac1 protein of SARS-CoV-2. Further, the five compounds can be stratified into three chemotypes based on their structures.

Conclusions

The study findings identified five drug molecules among three chemotypes that hinder SARS-CoV-2 Mac1-ADP-ribose binding in several experiments with IC50 values less than 100μM, restraining ADP-ribosylhydrolase activity, and proof of direct Mac1 binding. These chemotypes have a good chance of being derivatized and optimized into very potent SARS-CoV-2 Mac1 inhibitors. Compounds 1 and 6 exhibited IC50 values of around 10μM in the AS assay and directly bonded with Mac1. Further, compound 6 has remarkable selectivity for SARS-CoV-2 over human macrodomains, indicating that it should be developed further. 

Collectively, the study identified compounds that can be developed into potent Mac1 inhibitors and therapeutical agents for COVID-19 and other CoVs of interest.

*Important notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: ACE2 is necessary for SARS-CoV-2 infection and sensing by macrophages but not sufficient for productive viral replication. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock

Study explores macrophage susceptibility to SARS-CoV-2 virions

by Medical Finance
July 5, 2022
0

A recent study posted to the bioRxiv* preprint server investigated the susceptibility of macrophages to severe acute respiratory syndrome coronavirus...

Study: Methylene Blue Is a Nonspecific Protein-Protein Interaction Inhibitor with Potential for Repurposing as an Antiviral for COVID-19. Image Credit: Kateryna Kon/Shutterstock

Study finds methylene blue is a low-micromolar inhibitor of the the SARS-CoV-2 spike protein and ACE2 interaction

by Medical Finance
July 5, 2022
0

The rapid outbreak of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2), a novel coronavirus, caused the ongoing coronavirus disease 2019 (COVID-19). Among...

Study: Determinants of passive antibody effectiveness in SARS-CoV-2 infection. Image Credit: LuXiFeR Bowlo/Shutterstock

How the timing and dose of different types of passive antibody treatments predict protection from SARS-CoV-2 infection

by Medical Finance
July 5, 2022
0

Scientists have stated that the levels of neutralizing antibodies are strongly correlated with the prevention of symptomatic and severe coronavirus...

Blood proteoforms may help predict liver transplant rejection

Liver disease negatively impacted by lifestyle changes during the pandemic

by Medical Finance
July 5, 2022
0

Liver disease negatively impacted by lifestyle changes during the first year of the pandemic, according to a new study in...

Study: In silico analysis predicts a limited impact of SARS-CoV-2 variants on CD8 T cell recognition. Image Credit: artofvisionn/Shutterstock

Novel SARS-CoV-2 strains found to have low impact on CD8 T lymphocytes

by Medical Finance
July 5, 2022
0

In a recent study posted to the bioRxiv* pre-print server, researchers investigated the impact of mutations in the severe acute...

Study: A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues. Image Credit: Zerbor/Shutterstock

Model for investigating the effect of mutations on the binding affinity of the SARS-CoV-2 RBD-ACE2 complex

by Medical Finance
July 5, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers used a convolutional neural network (CNN) regression model (CNN_seq)...

Next Post
New evidence supports the link between growth-induced respiratory stress and fish reproduction

New evidence supports the link between growth-induced respiratory stress and fish reproduction

Researchers investigate how messenger substances signal inflammation during damaged cell removal

GlyNAC supplementation can increase lifespan and improve multiple age-associated defects

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • DNA Genetics 620x480
    Inversions in the human genome found to be more common than previously thought
  • ImageForNews 701742 16423941442503139
    Mutations in SARS-CoV-2 Omicron variant promote cell binding
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply